[{"orgOrder":0,"company":"Daavlin","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Hypericin","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Daavlin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Daavlin \/ Soligenix","highestDevelopmentStatusID":"10","companyTruncated":"Daavlin \/ Soligenix"}]

Find Clinical Drug Pipeline Developments & Deals for Hypericin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Legal Affairs
                          Not Confirmed
                          Legal Affairs
                          Not Confirmed

                          Details : Daavlin will exclusively manufacture the proprietary light device for use with SGX301 for the treatment of CTCL. Upon approval of SGX301 by the U.S FDA, Soligenix will promote SGX301 and the companion light device, and facilitate the direct purchase of t...

                          Product Name : SGX301

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 01, 2021

                          Lead Product(s) : Hypericin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Soligenix

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank